Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00199082
: September 20, 2005
Last Update Posted
: August 5, 2016
Information provided by (Responsible Party):
Nicola Goekbuget, Johann Wolfgang Goethe University Hospital
The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radiation therapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. A dose-reduced regimen is offered for patients estimated to be over 55 years, biologically.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
15 Years to 65 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Burkitt's leukemia or Burkitt's lymphoma or primary mediastinal large B-cell lymphoma or B-precursor lymphoblastic lymphoma or large cell anaplastic lymphoma
Age > 15 years
Written informed consent
Serious secondary diseases, including psychiatric conditions, under which the required therapy compliance is not to be expected
Secondary lymphoma following prior chemotherapy/radiotherapy or active second malignancy
Known severe allergy to foreign proteins
Pre-treatment other than 1 cycle CHOP or similar; < 1 week of another chemotherapy.
Pregnancy or nursing
Participation in other studies that interfere with study therapy